Drawing for BEAUFORT

USPTO serial 77600189

BEAUFORT

Reviewed by CopyMark Law Group

Reg. 3690806Status 800Registered
Filing date
Status date
Registration date
Sep 29, 2009
Examiner
GENOVESE, CARRIE A
Law office
GENERIC WEB UPDATE

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with BEAUFORT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy J. Lockhart

TIMOTHY J. LOCKHART WILLCOX & SAVAGE, P.C.440 Monticello Avenue, Suite 2200ATTN.: IP ADMINISTRATORNORFOLK, VA 23510-2243

Goods and services

ClassDescriptionStatusFirst use
035Regulatory submission management, namely, assisting others in preparing Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; database managementACTIVEJun 25, 2009
040Consulting services in the field of manufacturing compliance and validation, namely, providing technical advice related to the manufacture of pharmaceuticalsACTIVEJun 25, 2009
042Contract research organization (CRO) services, namely, monitoring of clinical trials for investigational drugs of biotech and pharmaceutical companies, clinical trial project management and quality assurance, medical writing of investigational drug protocols, and medical research in the nature of biostatistical analysis; consulting services in the field of conducting clinical trials, drug development, manufacturing environmental compliance and validation, advanced technology in the pharmaceutical field, and medical research in the nature of clinical benchmarking used to improve the performance of professionals in the fields of international health, the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, devices and biologicsACTIVEJun 25, 2009
045Legal research, namely, regulatory research in the pharmaceutical industry, biotechnology industry and the medical and diagnostics industry; consultation in the field of regulatory compliance to ensure validity and accuracy of regulatory submissions to the FDA by life sciences companies; conducting regulatory and compliance audits for others, namely, reviewing standards and practices to assure compliance with laws and regulations in the fields of pharmaceutical, veterinary, pharmacogenomic, biotechnical and medical products and devices; providing information relating to legal affairs, namely, providing regulatory information relating to the development and validation of drugs, devices and biologics; regulatory compliance consulting as it applies to clinical trials, namely, monitoring by clinical research administrators for compliance with regulations governing clinical trials; legal document preparation services, namely, preparation of Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; consulting services in the field of regulatory affairs and manufacturing compliance and validation, namely, regulatory compliance consulting as it applies to prescription drug sampling; consulting services in the field of clinical benchmarking and performance improvement, namely, providing independent review of clinical trials involving human subjects in the nature of reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of researchACTIVEJun 25, 2009

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 7, 2019NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Mar 7, 2019RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Mar 7, 201989AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Mar 7, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 3, 2019E89RTEAS SECTION 8 & 9 RECEIVED
Sep 29, 2018REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 20, 2016CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 20, 2016COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 25, 2015NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Sep 25, 20158.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Sep 24, 2015APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 14, 2015ES8RTEAS SECTION 8 RECEIVED
Apr 7, 2010ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 29, 2009R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Aug 25, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 25, 2009ALIEASSIGNED TO LIE
Aug 20, 2009CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Aug 20, 2009IUAAUSE AMENDMENT ACCEPTED
Aug 7, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Aug 6, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 4, 2009AUPCAMENDMENT TO USE PROCESSING COMPLETE
Aug 4, 2009IUAFUSE AMENDMENT FILED
Aug 3, 2009EAAUTEAS AMENDMENT OF USE RECEIVED
Jul 29, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 29, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 29, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 3, 2009GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2009GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 27, 2009DOCKASSIGNED TO EXAMINER
Oct 29, 2008MPMKNOTICE OF PSEUDO MARK MAILED
Oct 28, 2008NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance